Services / Activities

- Feasibility assessment for centre participation and recruitment (performed at short notice)

- Help in achieving recruitment rate by contacting directly and regularly the participating centres

- Scientific advice including contributions to clinical trial design

- Certification and training of technical personnel

- Facilitation of administrative setup of contracts with Clinical Trial Centres

- Subspecialty clinical trial research networks

- Access to the EVICR.net Reading Centre Network

Ongoing Services

1. Investigator-Driven Clinical Trials

PROTOCOL nº: ECR-RET-2010-02
TITLE: Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures.

PURPOSE: To identify eyes that show worsening and disease progression (progressor phenotypes).

ClinicalTrials.gov Identifier: NCT01145599

 

PROTOCOL nº: ECR-CCRS-2010-01
TITLE: Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes.

PURPOSE: To determine the average values of human ocular biometry and to correlate these values with visual function.

ClinicalTrials.gov Identifier: NCT01173614

PROTOCOL nº: ECR-RET-2011-03 (EUROCONDOR)
TITLE: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy
PURPOSE: To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes.

EU funded  FP7- HEALTH 2011 project: 278040-2

EudraCT Nº: 2012-001200-38

ClinicalTrials.gov Identifier: NCT01726075

 

PROTOCOL nº: ECR-GLC-2012-04 (STRONG)
TITLE: Early onset of Neovascular Glaucoma

PURPOSE: To study the natural course of the disease, to determine risk factors for the occurrence of neovascular glaucoma and to identify biomarkers that better characterize the course of the disease. At the same time to test the efficacy of aganirsen for the treatment of neovascular glaucoma in about three hundred patients in 35 clinical centres across Europe.

EU funded FP7- HEALTH 2012 project: 305321

 

PROTOCOL: EUR-USH

TITLE: European young investigators network for Usher syndrome
PURPOSE: Bring new insights towards the understanding of Usher Syndrome.

EU funded E-RARE 2 project: 12-058

 2. Industry-Driven Clinical Trials

PROTOCOL: POLARIS

TITLE: A prospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens in patients with diabetic macular edema (DME) with central involvement.

PURPOSE: To evaluate changes in visual acuity (ETDRS/Snellen) based on clinical management patterns and resource utilization in patients with DME with  central involvement starting treatment with an approved
anti-VEGF therapy.

3. Certification of Refraction and Visual Acuity Technicians

3.1 BCVA Technician’s Certification for Allergan

Protocol 150998-001

Protocol 206207-024

Protocol MAF/AGN/OPH/RET/004

Protocol 192024-041D